Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data

被引：0

作者：

Kim A. Papp

Melinda Gooderham

Ignacio Dei-Cas

Adriana LopezTello

Juan C. Garcia-Rodriguez

Carmen Yris Taveras

Azucena Hernández Rousselin

Alberto Lavieri

Mónica Maiolino

Delfina Guadalupe Villanueva Quintero

Lenka Rihakova

Mariano Salibe

Wilfran Pertuz

机构：

[1] K Papp Clinical Research and Probity Medical Research,SKiN Centre for Dermatology and Probity Medical Research

[2] Peterborough and Queen’s University,HIGA Presidente Perón, Servicio de Dermatología, Facultad Medicina UBA

[3] Psoriasis BsAs,undefined

[4] NEKI Servicios Medicos,undefined

[5] Vicente Guerreo,undefined

[6] DermaAdvance Center,undefined

[7] Hospital Regional Universitario Jose Maria Cabral Y Baez,undefined

[8] Hospital Roosevelt,undefined

[9] Calzada Roosevelt,undefined

[10] Private Clinic,undefined

[11] Consultorios Médicos Dr Bouzo,undefined

[12] Grupo Clínico CATEI (Centro de Atención en Enfermedades Inflamatorias) Sociedad Civil,undefined

[13] Novartis Pharmaceuticals Canada Inc.,undefined

[14] Novartis Argentina S.A.,undefined

[15] Novartis Pharma Logistics,undefined

[16] Inc.,undefined

[17] Panama,undefined

来源：

Dermatology and Therapy | 2023年 / 13卷

关键词：

Latin America; Plaque psoriasis; PURE registry; Real-world; Secukinumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：269 / 283

页数：14

共 50 条

[31] Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling
Liu, Yixiao
Xu, Ling
Wang, Xinrui
Wu, Lijuan
Cai, Ruifen
Li, Lujin
Zheng, Qingshan
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (10) : 999 - 1008
[32] Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Bagel, Jerry
Nia, John
Hashim, Peter W.
Patekar, Manmath
de Vera, Ana
Hugot, Sophie
Sheng, Kuan
Xia, Summer
Gilloteau, Isabelle
Muscianisi, Elisa
Blauvelt, Andrew
Lebwohl, Mark
DERMATOLOGY AND THERAPY, 2018, 8 (04) : 571 - 579
[33] Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis
Armstrong, April W.
Feldman, Steven R.
Korman, Neil J.
Meng, Xiangyi
Guana, Adriana
Nyirady, Judit
Herrera, Vivian
Zhao, Yang
JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (03) : 200 - 205
[34] Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
Blauvelt, Andrew
Armstrong, April W.
Langley, Richard G.
Gebauer, Kurt
Thaci, Diamant
Bagel, Jerry
Guenther, Lyn C.
Paul, Carle
Randazzo, Bruce
Flavin, Susan
Hsu, Ming-Chun
You, Yin
Reich, Kristian
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2317 - 2324
[35] Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Strober, Bruce
Ferris, Laura
Duffin, Kristina Callis
Janak, Jud C.
Sima, Adam P.
Eckmann, Thomas
Patel, Manish
Photowala, Huzefa
Garg, Vishvas
Armstrong, April
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (01) : 82 - 90
[36] Rapid response of nail psoriasis to secukinumab in patients with moderate to severe psoriasis after 12 weeks of treatment with a total of 24 weeks of follow-up
Go, Gang Min
Hong, Yong Jun
Lee, Hyun Ji
Kim, Miri
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024, 65 (03) : e13 - e20
[37] Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
Zhang, Jinsui
Xia, Zemin
Guo, Wanjie
Ren, Xiaoxiao
Liu, Fang
Ratnaparkhi, Gargi
Pagada, Amit
Subramanian, Subhashini
Hu, Min
Chen, Wen
DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2681 - 2696
[38] Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients
Huang, He
Cai, Ming-Long
Hong, Xiao-Jie
Zheng, Li-Jun
Hu, Zhu-Lin
Yuan, Tao
Li, Wei-Ran
Sheng, Yu-Jun
Zhang, Xue-Jun
EUROPEAN JOURNAL OF DERMATOLOGY, 2020, 30 (05) : 554 - 560
[39] Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
Jinsui Zhang
Zemin Xia
Wanjie Guo
Xiaoxiao Ren
Fang Liu
Gargi Ratnaparkhi
Amit Pagada
Subhashini Subramanian
Min Hu
Wen Chen
Dermatology and Therapy, 2023, 13 : 2681 - 2696
[40] Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients
He Huang
Ming-Long Cai
Xiao-Jie Hong
Li-Jun Zheng
Zhu-Lin Hu
Tao Yuan
Wei-Ran Li
Yu-Jun Sheng
Xue-Jun Zhang
European Journal of Dermatology, 2020, 30 : 554 - 560

← 1 2 3 4 5 →